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OBJECTIVE—The oxidation of LDLs is considered a key step in
the development of atherosclerosis. How LDL oxidation contrib-
utes to atherosclerosis remains poorly deﬁned. Here we report
that oxidized and glycated LDL (HOG-LDL) causes aberrant
endoplasmic reticulum (ER) stress and that the AMP-activated
protein kinase (AMPK) suppressed HOG-LDL–triggered ER
stress in vivo.
RESEARCH DESIGN AND METHODS—ER stress markers,
sarcoplasmic/endoplasmic reticulum Ca
2 ATPase (SERCA) ac-
tivity and oxidation, and AMPK activity were monitored in
cultured bovine aortic endothelial cells (BAECs) exposed to
HOG-LDL or in isolated aortae from mice fed an atherogenic diet.
RESULTS—Exposure of BAECs to clinically relevant concen-
trations of HOG-LDL induced prolonged ER stress and reduced
SERCA activity but increased SERCA oxidation. Chronic admin-
istration of Tempol (a potent antioxidant) attenuated both
SERCA oxidation and aberrant ER stress in mice fed a high-fat
diet in vivo. Likewise, AMPK activation by pharmacological
(5-aminoimidazole-4-carboxymide-1--D-ribofuranoside, met-
formin, and statin) or genetic means (adenoviral overexpression
of constitutively active AMPK mutants) signiﬁcantly mitigated
ER stress and SERCA oxidation and improved the endothelium-
dependent relaxation in isolated mouse aortae. Finally, Tempol
administration markedly attenuated impaired endothelium-de-
pendent vasorelaxation, SERCA oxidation, ER stress, and ath-
erosclerosis in ApoE
/ and ApoE
//AMPK2
/ fed a high-fat
diet.
CONCLUSION—We conclude that HOG-LDL, via enhanced
SERCA oxidation, causes aberrant ER stress, endothelial dys-
function, and atherosclerosis in vivo, all of which are inhibited by
AMPK activation. Diabetes 59:1386–1396, 2010
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DL oxidation and glycation are known to promote
atherosclerosis through several mechanisms that
include promoting vascular proinﬂammatory re-
sponses, intracellular oxidative stress, and apo-
ptosis associated with endothelial dysfunction (1,2). In
addition, LDL oxidation is greatly enhanced by LDL glyca-
tion (3,4). For example, glycation of LDL slows the clear-
ance of these particles from the circulation (5), increases
their susceptibility to oxidative damage (6), enhances
entrapment of extravasated particles in the vascular sub-
intimal space, and increases chemotactic activity of mono-
cytes (7). The presence of both glycated LDL and
glycoxidized LDL in human atherosclerotic plaques has
been conﬁrmed by immunochemical methods both in vivo
and in vitro (8–10). Increasing evidence suggests that
glycation and oxidation of LDL induces apoptosis in
arterial wall cells (11,12), and glycoxidized LDL triggers
apoptosis in vascular smooth muscle cells (13,14). Over-
all, glycation of LDL promotes the formation of oxidized
LDL, and this phenomenon contributes to accelerated
atherosclerosis, an important pathologic corollary of
diabetes.
Endoplasmic reticulum (ER) stress has been linked to a
wide range of human pathologies including diabetes (15–
17), obesity (16,17), atherosclerosis (18), cancer, neurode-
generative disorders, and inﬂammatory conditions. ER
stress may be triggered by high glucose, oxidative stress,
Ca
2 overload, ischemia, and hypoxia. In addition, it
causes the accumulation of unfolded and misfolded pro-
teins, leading to an “unfolded protein response” (19). The
normal ER is the principal site of protein synthesis,
folding, and maturation. In unfolded protein response,
unfolded or misfolded proteins are sent to the cytoplasm
by a “retro-translocation mechanism” to be degraded by
the ubiquitin proteasome system (20).
AMP-activated protein kinase (AMPK), a sensor of
cellular energy status, plays a critical role in controlling
the cell’s energy balance and metabolism (21), and
activation of AMPK is an important defensive response
to stress (22). AMPK activation is neuroprotective (23),
and also mediates at least some cardiovascular protec-
tive effects of drugs such as hydroxymethylglutaryl-CoA
reductase inhibitors (e.g., the statins such as pravastatin
and atorvastatin) and metformin (a biguanide that acti-
vates AMPK) (24,25). Activation of AMPK protects
cardiomyocytes against hypoxic injury through attenu-
ation of ER stress (26). However, whether AMPK alters
oxidized LDL-induced ER stress in endothelial cells has
not been investigated to date. In this study, we report
that oxidized, glycated-LDL (HOG-LDL) via the oxida-
tion and inhibition of sarcoplasmic/endoplasmic reticu-
lum Ca
2 ATPase (SERCA), triggers ER stress in
endothelial cells in vivo. In addition, we have uncovered
evidence suggesting that AMPK activation attenuates
ER stress by inhibiting SERCA oxidation caused by
HOG-LDL.
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Materials. Antibodies against phospho-AMPK, phospho-acetyl-CoA carboxy-
lase (ACC), phospho-eukaryotic translation initiation factor 2 (eIF2),
anti-endothelial nitric oxide synthase, phospho–Jun NH2-terminal kinase
(JNK), and 3-nitrotryosine were obtained from Cell Signaling Biotechnology
(Danvers, MA). The antibodies against phospho-PKR (protein kinase R)-like
ER kinase (PERK), X-box binding protein 1 (XBP-1), and SERCA, scrambled
small interfering RNA (siRNA), and the speciﬁc siRNA for calcium/calmodu-
lin-dependent protein kinase kinase 2 (CaMKK2), SERCA2, and p67
phox were
obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Antibodies
against glucose-regulated protein 78 (GRP78) and oxidized LDL (ox-LDL)
were from Abcam (Cambridge, MA). Antibody against activating transcrip-
tion factor 6 (ATF6) was obtained from Imgenex (San Diego, CA).
3-(4-morpholinyl)sydnone imine hydrochloride (SIN-1) was from Dojindo
Laboratories USA (Rockville, MD). 5-aminoimidazole-4-carboxymide-1--
D-ribofuranoside (AICAR) was from Toronto Research Chemicals Inc.
(North York, ON, Canada). Fluo-4 NW kits were obtained from Invitrogen
Inc. (Carlsbad, CA). All other chemicals, if not indicated, were purchased
from Sigma-Aldrich (St. Louis, MO).
Animals. All mice were housed in temperature-controlled cages under a 12-h
light-dark cycle and given free access to water and normal chow. AMPK2
/
mice that had been backcrossed onto a C57BL/6 background were crossed
with ApoE
/ mice (The Jackson Laboratory), also on the C57BL/6 back-
ground, to generate ApoE
//AMPK2
/ mice. Accelerated atherosclerosis
was induced by feeding the mice a Western diet containing 0.21% cholesterol
and 21% fat (D12079B; Research Diets Inc.). This diet was administered
beginning at 5 weeks of age and continued for 8 consecutive weeks. At 5
weeks of age, Tempol (Sigma-Aldrich) was also added to the drinking water (1
mmol/l) for 8 weeks. ApoE
/ mice fed with normal chow were used as
controls. The animal protocol was reviewed and approved by the University of
Oklahoma Institutional Animal Care and Use Committee.
Preparation of N-LDL and oxidized and glycated LDL. Native LDL
(N-LDL) and HOG-LDL were prepared as described previously (27). Final
preparations were dialyzed extensively against PBS buffer. Characterization of
native and HOG-LDL was done by gel electrophoresis (ﬂuorescence at 360 nm
excitation/430 nm emission, and absorbance at 234 nm, as described previ-
ously [27,28]). The study protocol was approved by the Institutional Review
Board at the University of Oklahoma Health Sciences Center.
Cell culture and treatment. Both bovine aortic endothelial cells (BAECs)
and human umbilical vein endothelial cells (HUVECs) were cultured in
endothelial basal medium with 2% FBS. After conﬂuence, cells were incubated
with HOG-LDL at the concentrations and times indicated. Cells exposed to the
same concentrations of N-LDL were used as controls. If needed, pharmaco-
logical reagents, including 1,2-B is BAPTA-AM (10 mol/l), AICAR (1 mmol/l),
or Tempol (10 mol/l), were added 30 min prior to the addition of N-LDL or
HOG-LDL.
Downregulation of gene expression by siRNA. Conﬂuent HUVECs were
transfected with control or gene-speciﬁc siRNA according to manufacturer’s
recommendations. To improve suppression of the target gene, two rounds of
consecutive siRNA gene silencing were performed. The efﬁciency of siRNA-
silenced genes was evaluated by Western blotting of the targeted protein with
speciﬁc antibodies.
Adenoviral preparation and infection. Adenoviral vector AMPK-CA (a
constitutively active AMPK mutant) was generated as previously reported
(25). Adenoviral vector AMPK-DN (a dominant-negative mutant of AMPK) was
generated by subcloning the cDNA encoding AMPK1-DN-(D159A) into
adenoviral vector pAdEasy-1.
Conﬂuent cells were infected with adenoviruses at multiplicity of infection
of 50 for 36 h, as described previously (25). Adenovirus encoding green
ﬂuorescent protein (GFP) was used as control. Under this condition, the
expression efﬁciency was 80% as seen by GFP expression.
Preparation of cytosolic and membrane fractions. Cellular cytosolic and
membrane fractions were prepared as described previously (25). Transloca-
tion of p47
phox subunit of NAD(P)H oxidase was determined in Western blot.
Assays of the endothelium-dependent and –independent vasorelax-
ation. The endothelium-dependent (assays of bioactive nitric oxide [NO]) and
-independent (assays of vascular smooth muscle responsiveness to nitric
oxide donor sodium nitroprusside) vasorelaxation was measured as described
previously (27).
Measurement of intracellular [Ca
2]i, SERCA activity, cysteine 674
labeling, and ratiometric analysis of SERCA function. Intracellular
calcium concentration ([Ca
2]i) was measured using a Fluo-4 NW kits in
accordance with manufacturer’s recommendations with the ﬂuorophore ex-
cited at 485 nm and detection at 520 nm (27). [Ca
2]i was expressed as a
percentage of control. SERCA activity was measured as described previously
(29). Biotinylated-iodoacetamide (b-IAM) labeling of SERCA cysteine 674 was
performed according to the methods described by Tong et al. (30). Proteins
were separated by SDS-PAGE, and b-IAM labeled Cys674-SERCA was de-
tected using SERCA-speciﬁc antibody. Ratiometric Ca
2 measurement, which
can assay SERCA function dynamically, was conducted as described previ-
ously (31).
Determination of serum cholesterol, triglyceride, and blood glucose
levels. Mice underwent a 14- to 15-h fast before blood samples were collected.
Blood glucose levels were determined by applying tail blood to an OneTouch
Ultra Blood Glucose Monitoring System (LifeScan). Serum cholesterol and
triglyceride levels were measured enzymatically, using Inﬁnity reagents from
Thermo DMA according to the manufacturer’s instructions.
Atherosclerotic lesion analysis. After being fed the Western diet for 8
weeks, mice were fasted for 14 h and then were anesthetized and killed. The
heart and aortic tissue were removed from the ascending aorta to the ileal
bifurcation and placed in 4% paraformaldehyde for 16 h. For analyzing the
lesion area in the aortic root, the heart was dissected from the aorta,
embedded in Polyfreeze tissue freezing medium (Polysciences, Inc.), and
sectioned (5-m thickness). Four sections representing every tenth serial
section over a distance of 200 m were collected from each mouse and
stained with Oil Red O for neutral lipids, and counterstained with hematoxylin
to visualize the nuclei. Plaques were imaged with an Olympus microscope
connected to a QImaging Retiga CCD camera. The aortic lesion size of each
animal was obtained by the averaging of lesion areas in four sections from the
same mouse. For analyzing the lesion area in the aortic arch, the intimal
surface was exposed by a longitudinal cut from the ascending arch to 5 mm
distal of the left subclavian artery to allow the lumen of the aortic arch to be
laid ﬂat. The aorta was rinsed for 5 min in 75% ethanol, stained with 0.5%
Sudan IV in 35% ethanol and 50% acetone for 15 min, destained in 75% ethanol
for 5 min, and then rinsed with distilled water. Digital images of the aorta were
captured under a stereomicroscope, and the lesion area was quantiﬁed from
the aortic arch to 5 mm distal of the left subclavian artery using Alpha Ease FC
software (Version 4.0; Alpha Innotech).
Immunocytochemistry staining. Immunocytochemistry stainings for oxi-
dized LDL and ER stress markers were performed as described previously
(32).
Statistics. Results were analyzed with a one-way ANOVA with appropriate
post hoc analysis of results as well as Student t test. Values were expressed as
mean  SD. P 	 0.05 was considered statistically signiﬁcant.
RESULTS
HOG-LDL increases ER stress in endothelial cells. We
had previously reported (27) that exposure of BAECs to
HOG-LDL impairs endothelial function by inducing cal-
pain-mediated endothelial NO synthase degradation in a
reactive oxygen species (ROS)– and Ca
2-dependent man-
ner. Whether HOG-LDL alters ER stress was not known.
To determine the effect of HOG-LDL on ER stress, conﬂu-
ent BAECs were exposed to HOG-LDL at a concentration
of 100 g/ml, which is considered to be pathologically
relevant to type 2 diabetes (28), for 30 min to 6 h. BAECs
exposed to N-LDL (100 g/ml) were used as controls. As
depicted in Fig. 1A, HOG-LDL but not N-LDL, markedly
increased the detection of p-PERK and p-eIF2, two
established ER stress markers, as early as 30 min after
HOG-LDL exposure. Concomitantly, HOG-LDL also in-
creased the expression of GRP78 and the cleavage of ATF6
(Fig. 1A).
The effects of HOG-LDL appeared to be dose dependent.
Low concentration of HOG-LDL (50 g/ml) markedly
increased the detection of p-PERK, p-eIF2, and p-JNK in
BAECs at 6 h (Fig. 1B and C). ER stress markers (p-PERK,
p-eIF2, and p-JNK) increased as the doses of LDL in-
creased (25–200 g/ml) within 6-h exposure.
Ca
2chelation abolishes HOG-LDL–induced ER stress.
Because exposure of BAECs to HOG-LDL elevates intra-
cellular calcium [Ca
2]i in BAECs (27), we next deter-
mined whether the rise of [Ca
2]i contributed to increased
detection of ER stress. We ﬁrst determined whether cal-
cium mobilizing reagents triggered ER stress in BAECs. As
expected, exposure of BAECs to calcimycin, a well-known
Ca
2 mobilizer, markedly increased the detection of ER
Y. DONG AND ASSOCIATES
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meﬂouquine, or SIN-1, all of which are known to increase
intracellular [Ca
2]i, also increased ER stress in BAECs
(supplementary Fig. 1, available in an online appendix at
http://diabetes.diabetesjournals.org/content/early/2010/03/
10/db09-1637/suppl/DC1).
It was important to determine whether chelating [Ca
2]i
reversed the effects of HOG-LDL on ER stress. Pretreat-
ment of BAECs with BAPTA-AM (10 mol/l) signiﬁcantly
inhibited HOG-LDL–induced ER stress (Fig. 1D and sup-
plementary Fig. 1C), implying that a rise in [Ca
2]i was
critical for HOG-LDL–enhanced ER stress.
HOG-LDL–triggered ER stress is oxidative stress de-
pendent. As peroxynitrite (ONOO
) is known to increase
both intracellular calcium and ER stress (33), we next
determined whether ONOO
 mediated the effects of HOG-
LDL. 3-nitrotyrosine (3-NT)–positive proteins are consid-
ered a footprint of ONOO
 in cultured cells. We ﬁrst
assayed whether HOG-LDL increased the levels of 3-NT.
As depicted in Fig. 2A, exposure of BAECs to HOG-LDL,
but not N-LDL, dose-dependently increased the levels of
3-NT–positive proteins, implying that HOG-LDL increased
ONOO
 in endothelial cells.
ONOO
 is a potent oxidant formed by the combination
of superoxide and NO. Our previously published data (27)
demonstrate that HOG-LDL enhances both superoxide and
ONOO
 upon its reaction with NO by activating NAD(P)H
oxidase. Therefore, it was interesting to determine
whether inhibition of NAD(P)H oxidase or scavenging
superoxide altered HOG-LDL–triggered ER stress. To this
end, BAECs were pretreated with apocynin, a potent
inhibitor for NAD(P)H oxidase, or Tempol, a superoxide
scavenger, prior to the addition of HOG-LDL. As shown in
Fig. 2B, both apocynin and Tempol signiﬁcantly attenuated
HOG-LDL–induced ER stress.
Next, we determined whether genetic inhibition of
NAD(P)H oxidase attenuated ER stress caused by HOG-
LDL. As depicted in Fig. 2C, transfection of p67
phox-
speciﬁc siRNA signiﬁcantly reduced the levels of p67
phox,
an essential component of NAD(P)H oxidases. Further,
transfection of p67
phox-speciﬁc siRNA, but not control
siRNA, abrogated HOG-LDL–induced ER stress (Fig. 2C
and D). Taken together, our results suggest that NAD(P)H
oxidase–derived ROSs were required for HOG-LDL–trig-
gered ER stress.
Inhibition of SERCA increases ER stress in endothe-
lial cells. Because SIN-1, an ONOO
 donor, increased
both intracellular Ca
2 and ER stress (supplementary Fig.
1B and C), we next investigated how ONOO
 increased
intracellular Ca
2 in BAECs. Because SERCA is a key
enzyme that controls Ca
2 transfer from the cytosol to the
ER lumen and its inhibition is known to cause aberrant ER
stress in various cell types (34), we hypothesized that
ONOO
 generated during HOG-LDL exposure might alter
SERCA function resulting in increased levels of [Ca
2]i.
Indeed, exposure of BAECs to thapsigargin, a speciﬁc
SERCA inhibitor, triggered ER stress in both a time- and
concentration-dependent manner in BAECs (supplemen-
tary Fig. 2A and B).
To avoid potential off-target effects of thapsigargin, we
next determined whether genetic inhibition of SERCA2
altered ER stress in endothelial cells. Because bovine-
speciﬁc SERCA siRNA is not available, we performed
siRNA experiments in HUVECs, in which HOG-LDL
caused a Tempol-sensitive aberrant ER stress and SERCA
inhibition (supplementary Fig. 3). As expected, gene si-
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ER stress in endothelial cells (supplementary Fig. 2C and
D), suggesting SERCA inhibition triggered ER stress in
endothelial cells.
HOG-LDL reduces SERCA activity along with in-
creased detection of SERCA oxidation. To explore
how HOG-LDL exposure could trigger ER stress in endo-
thelial cells, we ﬁrst determined whether HOG-LDL sup-
pressed SERCA activity. As depicted in Fig. 3A, HOG-LDL
signiﬁcantly inhibited SERCA activity in BAECs. However,
HOG-LDL had no effect on the expression of SERCA(s) in
endothelial cells (Fig. 3B), suggesting that HOG-LDL–
induced suppression of SERCA activity was independent
of transcriptional and translational regulation of SERCA.
Because Cys674 of SERCA is reported to be oxidized
and suppressed by ROSs (30), we next determined
whether HOG-LDL increased the SERCA oxidation at
Cys674. We ﬁrst determined whether inhibition of
NAD(P)H oxidase with apocynin or scavenging superox-
ide with Tempol, both of which suppressed HOG-LDL–
induced ER stress (Fig. 2B), also alleviated the effects of
HOG-LDL on SERCA activity and SERCA oxidation on
Cys674. As depicted in Fig. 3A, Tempol restored SERCA
activity in HOG-LDL–treated cells. Similarly, apocynin
ablated the reduction in SERCA activity induced by HOG-
LDL (Fig. 3C). Consistently, HOG-LDL signiﬁcantly in-
creased oxidation of Cys674 (Fig. 3D). Furthermore,
Tempol prevented HOG-LDL–enhanced SERCA oxidation
(Fig. 3D). Cumulatively, these ﬁndings suggest that HOG-
LDL attenuates SERCA activity via ROS-mediated oxida-
tion of the Cys674 residue of these ATPases.
AICAR restores intracellular calcium and SERCA
activity but suppresses ER stress. We had reported that
AMPK activation by AICAR reduces oxidative stress in
diabetes (35). It was therefore interesting to investigate
whether AMPK activation alleviated SERCA oxidation and
consequent ER stress caused by HOG-LDL. Short expo-
sure (	3 h) of BAECs to HOG-LDL (100 g/ml) markedly
increased the detection of AMPK phosphorylation at
Thr172 (Fig. 4A), an index for AMPK activation. AICAR
signiﬁcantly enhanced AMPK Thr172 phosphorylation
caused by HOG-LDL alone (Fig. 4A).
We next determined whether the reduction of ER stress
was via a reduction of [Ca
2]i. As depicted in Fig. 4B,
AICAR blocked HOG-LDL–induced [Ca
2]i rise and re-
duced the markers of ER stress (Fig. 4C).
As apocynin ablated HOG-LDL–induced ER stress and
SERCA oxidation, it was logical to determine whether
AMPK activation by AICAR lowered HOG-LDL–induced
ER stress by suppressing the activation of NAD(P)H
oxidase. As depicted in Fig. 4D, HOG-LDL exposure in-
creased the membrane translocation of p47
phox, a key step
for NAD(P)H oxidase assembly and activation. Impor-
tantly, AICAR suppressed the effects of HOG-LDL on
p47
phox translocation (Fig. 4D).
We next assayed whether AICAR attenuated SERCA
inhibition caused by HOG-LDL. AMPK activation by
AICAR inhibited HOG-LDL–induced reduction in SERCA
activity in BAECs (Fig. 4E). To further conﬁrm the effect of
AICAR on SERCA function, [Ca
2]i was monitored using
ratiometric measurements dynamically (31). As shown in
Fig. 4F, compared with N-LDL–treated cells, HOG-LDL–
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[Ca
2]i to the ER lumen, which is in line with an earlier
report (28). Importantly, AICAR pretreatment abolished
the effects of HOG-LDL (Fig. 4F). These data further
support that AICAR alleviates the reduction of SERCA
function caused by HOG-LDL.
AMPK protects SERCA activity and consequent ER
stress caused by HOG-LDL. To exclude potential off-
target effects of AICAR, we tested whether genetic activa-
tion or inhibition of AMPK modulates HOG-LDL–induced
ER stress. Overexpression of AMPK-CA, a constitutively
active AMPK mutant, suppressed HOG-LDL– and calcimy-
cin-induced ER stress (Fig. 5A and B). Conversely, AMPK
inhibition by overexpression of AMPK-DN, an AMPK dom-
inant negative mutant, signiﬁcantly accentuated ER stress
induced by either HOG-LDL or calcimycin (Fig. 5C and D).
Concomitantly, overexpression of AMPK-CA maintained
SERCA activity when challenged with HOG-LDL, whereas
AMPK-DN failed to maintain SERCA activity (Fig. 5E).
Taken together, our results suggest that AMPK activation
suppresses ER stress caused by HOG-LDL through main-
taining SERCA activity.
AMPK activation abolishes HOG-LDL–induced ER
stress in isolated mouse aorta ex vivo. To further test
the role of AMPK in response to HOG-LDL–induced ER
stress and consequent vascular dysfunction, we assayed
the effects of metformin and statins, two clinically used
AMPK activators, in isolated aortas ex vivo. Metformin or
simvastatin was added 30 min prior to HOG-LDL exposure.
As shown in Fig. 6A, both metformin and statin treatment
activated AMPK when aortic rings were incubated with or
without HOG-LDL. HOG-LDL induced ER stress, as indi-
cated by stress markers p-PERK and p-eIF2 (Fig. 6B).
Pretreatment of isolated aortae with metformin or st-
atins ablated the effects of HOG-LDL on ER stress (Fig.
6B and C).
Next, we assessed the effects of AMPK activation on
acetylcholine (ACh)–induced endothelium-dependent re-
laxation under ex vivo conditions. As indicated in Fig. 6D,
HOG-LDL impaired ACh-induced relaxation. Pretreatment
with metformin or simvastatin, which did not alter basal
ACh-induced relaxation, reversed the reduction of Ach-
induced vasorelaxation caused by HOG-LDL. In addition,
the endothelium-independent vasorelaxation, as assayed
by monitoring vasorelaxation to sodium nitroprusside, a
NO donor, was unchanged among these groups (data
not shown), suggesting unchanged function of vascular
smooth muscle cells in terms of NO. Overall, these
results suggest that AMPK activation is sufﬁcient to
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HOG-LDL.
AMPK2 deletion reduces SERCA activity in parallel
with ER stress in vivo. It was important to determine
whether AMPK is essential in maintaining SERCA activity
and inhibiting ER stress in vivo. Compared with ApoE
/
mice fed normal diet, ApoE
/ mice fed high-fat diet
(HFD) had a reduced SERCA activity and exhibited
greater degree of ER stress in the aorta (Fig. 7A–C). In
addition, AMPK2 depletion caused further reduction of
SERCA activity with higher degree of ER stress in the
aorta than ApoE counterparts (Fig. 7A–C).
Chronic administration of Tempol inhibits ER stress
but protects SERCA activity. Next, we determined
whether chronic administration of Tempol, a potent anti-
oxidant, prevented SERCA oxidation and attenuated ER
stress in vivo. As shown in Fig. 7C, Tempol treatment
protected SERCA activity from reduction, suggesting that
oxidation played a critical role in the reduction of SERCA
activity. Importantly, Tempol markedly suppressed ER
stress in both ApoE
/ and ApoE
//AMPK2
/ mice in
vivo (Fig. 7A and B). Taken together, our data imply that
inhibition of SERCA oxidation is able to suppress ER
stress in vivo.
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proves the endothelium-dependent vasorelaxation in
both ApoE
/ and AMPK2
//ApoE
/ mice. Com-
pared with C57BL6 mice, the endothelium-dependent va-
sorelaxation in response to acetylcholine was normal in
mice fed normal mouse chow (data not shown). The
endothelium-dependent relaxation in ApoE
/ mice fed
HFD was signiﬁcantly less than those of ApoE
/ mice fed
normal mouse chow (data not shown). In addition, the
endothelium-dependent relaxation in HFD-fed ApoE
//
AMPK2
/ mice was further reduced compared with
ApoE
/ mice with HFD (Fig. 7D). Importantly, Tempol
administration markedly attenuated impaired endothelium-
dependent vasorelaxation in ApoE
//AMPK2
/ mice
(Fig. 7D) but had no effect on the endothelium-indepen-
dent vasorelaxation (data not shown).
Tempol treatment reduces ox-LDL, ER stress, and
aortic lesion progression in ApoE
/ mice. Next, we
evaluated whether Tempol altered the levels of oxidized
LDL, ER stress, and aortic lesions in ApoE
/ mice.
Compared with normal diet, HFD signiﬁcantly increased
ox-LDL, ER stress, and aortic lesion in ApoE
/ mice (Fig.
7E and F). Further, Tempol reduced the levels of oxidized
LDL, ER stress markers, and aortic lesion areas (Fig. 7E
and F).
Tempol does not affect serum lipid or blood glucose
levels. Next, we compared metabolic parameters among
ApoE
/ and ApoE
//AMPK2
/ mice. No differences
in blood glucose, serum cholesterol, and triglyceride were
observed between ApoE
//AMPK2
/ and ApoE
/
mice (Table 1). Tempol treatment did not affect blood
glucose and triglyceride levels in both groups but in-
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FIG. 5. AMPK activation attenuates HOG-LDL–enhanced ER stress in
BAECs. BAECs were infected with adenovirus AMPK-DN or AMPK-CA
for 36 h; adenovirus GFP served as control. Infected BAECs were
treated with calcimycin, N-LDL, and HOG-LDL for 6 h. ER stress markers
were measured in Western blots using speciﬁc antibodies. A and B:
Adenoviral AMPK-CA suppressed calcimycin- or HOG-LDL–induced ER
stress; n  3. *P < 0.05 HOG-LDL vs. controls; #P < 0.05 HOG-
LDLAMPK-CA vs. HOG-LDLGFP. C and D: Ad-AMPK-DN ampliﬁed
HOG-LDL– or calcimycin-induced ER stress, n  3. *P < 0.05 HOG-LDL
vs. controls; #P < 0.05 HOG-LDLAMPK-DN vs. HOG-LDL GFP. E:
Overexpression of constitutively active AMPK abolishes HOG-LDL–
induced reduction of SERCA activity. n  3. *P < 0.05 ad-GFPHOG-
LDL vs. ad-GFP or ad-AMPK-DN; #P < 0.05 AMPK-CAHOG-LDL vs.
ad-GFPHOG-LDL; †P < 0.05 AMPK-DN vs. AMPK-CA.
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//AMPK2
/ mice
(Table 1).
DISCUSSION
In this study, we have demonstrated that LDL oxidation
and glycation cause aberrant ER stress via the oxidation of
SERCA in endothelial cells. We have also provided evi-
dence that AMPK activation is effective in inhibiting HOG-
LDL–enhanced SERCA oxidation and consequent ER
stress in vivo. Finally, we found chronic administration of
Tempol restored SERCA activity, ER stress, endothelium
function, and atherosclerosis caused by HFD in vivo.
One of the most important ﬁndings in the present study
is that HOG-LDL increases ER stress by ROS-dependent
oxidation and inhibition of SERCA activity, a key enzyme
that controls intracellular [Ca
2] (34,36–39). We have
further found HOG-LDL increases the oxidation of Cys674,
a known site for SERCA glutathiolation and oxidation,
likely via NAD(P)H oxidase–derived ROSs. Our observa-
tions are in line with several published studies that have
demonstrated that SERCA is prone to oxidation at one of
its thiol groups under certain conditions (30,40,41) and
that its oxidation is signiﬁcantly increased in atheroscle-
rotic lesions (41). Importantly, we found that chronic
administration of Tempol signiﬁcantly inhibited ER stress,
endothelial dysfunction, and aortic lesions in vivo. Our
results are also consistent with a recent report in which
antioxidant metallothionein is reported to inhibit ER
stress caused by diabetes and angiotensin II (42). Thus,
ROS might be a common ER stress inducer in different cell
types including endothelial cells, vascular smooth muscle
cells, and myocytes.
Another important ﬁnding of the present study is that
AMPK activation suppresses ER stress by inhibiting
NAD(P)H oxidase–derived ROSs, a well-known ER stress
initiator that has been implicated in the progression of
atherosclerosis in many studies (43–46). Our unpublished
data suggest that AMPK2 deletion increases the expres-
sion of NAD(P)H oxidase subunits and NAD(P)H oxidase–
derived ROSs in endothelial cells. How AMPK suppresses
NAD(P)H oxidase remains undeﬁned but warrants further
investigation.
Circulating levels of oxidized LDL have been proposed
to be a predictor of secondary cardiovascular events
(47,48). Plasma levels of oxidized LDL correlate with
endothelial dysfunction and are reduced after lipid-lower-
ing therapy using apheresis or statins (49). The concentra-
tion of oxidized and oxidized glycated LDL in the
circulation in healthy individuals is thought to be low (1–5
g protein/ml). Because conventional lipid proﬁles are
often abnormal in type 2 diabetes including increased
triglycerides, normal or elevated levels of LDL, and re-
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FIG. 6. Genetic activation or inhibition of AMPK alters HOG-LDL–induced ER stress in ex vivo aortae. A: Aortic rings were cut (
3-mm length)
and pretreated with 2 mmol/l metformin or 50 mol/l simvastatin for 30 min, followed by addition of 100 g/ml HOG-LDL or N-LDL (latter as
control), with or without metformin or statin for up to 6 h. *P < 0.05 metformin or statin vs. controls; #P < 0.05 controls vs. metformin plus
HOG-LDL or statin plus HOG-LDL. B and C: ER stress markers were detected from set (A); n > 4 in each treatment. *P < 0.01 HOG-LDL vs. N-LDL;
#P < 0.01 HOG-LDLmetformin or HOG-LDLstatin vs. HOG-LDL alone. D: HOG-LDL impaired aortic relaxation, which can be restored by
metformin or statin. n  4 in each group. *P < 0.05 HOG-LDL vs. N-LDL or HOG-LDLmetformin or HOG-LDLstatin.
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FIG. 7. Inhibition of SERCA oxidation by antioxidant Tempol reduced ER stress and atherosclerosis in vivo. A and B: Supplement of antioxidant
Tempol signiﬁcantly reduced ER stress. ApoE
/ and ApoE
//AMPK2
/ mice exhibited ER stress when fed with HFD compared with ApoE
/
mice fed with normal diet (ND) or HFD, as described in the “Research Design and Methods” section. n  5. *P < 0.05 ApoE
/ with HFD vs.
ApoE
/ with ND; #P < 0.05 ApoE
//AMPK2
/ with HFD vs. ApoE
/ with HFD; †P < 0.05 ApoE
/ with HFD vs. Tempol-treated ApoE
/ with
HFD; ‡P < 0.05 ApoE
//AMPK2
/ plus HFD vs. Tempol-treated ApoE
//AMPK2
/ with HFD. C: Tempol supplementation protects aortic
SERCA activity in vivo. n  5. *P < 0.05 ApoE
/ with HFD vs. ApoE
/ with ND; #P < 0.05 ApoE
//AMPK2
/ with HFD vs. ApoE
/ with HFD;
†P < 0.05 ApoE
/ with HFD vs. Tempol-treated ApoE
/ with HFD; ‡P < 0.05 ApoE
//AMPK2
//HFD vs. Tempol-treated ApoE
//AMPK2
/
with HFD. D: Tempol supplement ablates HFD-induced reduction of acetylcholine-induced endothelium-dependent vasorelaxation in isolated
mouse aortae from ApoE
//AMPK2
/ with HFD vs. ApoE
/ with HFD. *P < 0.05 ApoE
/ with HFD vs. Tempol-treated ApoE
/ with HFD;
#P < 0.05 ApoE
//AMPK2
/ vs. Tempol-treated ApoE
//AMPK2
/ with HFD. E: Tempol administration reduces ox-LDL, ER stress, and
aortic lesion progression in ApoE
/ mice detected by immunostaining; n > 4 in each group. F: Tempol administration inhibits aortic lesions in
aortic roots and aortic arches (en face staining); n > 5 in each group. # and ‡ indicate P < 0.05 Tempol treatment vs. control in each group; †P <
0.05 ApoE
//AMPK2
/ vs. ApoE
/ in each group. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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LDL are enhanced by diabetes. Further, the levels of
HOG-LDL are likely to be much higher in the extravascular
environment such as aortic lesions, when LDLs are re-
tained in a less antioxidant-rich milieu and exposed to
pro-oxidant stresses. For example, Nishi et al. demon-
strated that in the general population, levels of oxidized
LDL are 
70-fold higher in arterial lesions than in the
circulation (50). For these reasons, we consider the con-
centrations of LDL proposed in this work to be a reason-
able estimate of those present in vivo. Thus, our ﬁndings
might be important for understanding the etiology of
atherosclerosis.
In summary, the present study has demonstrated that
activation of AMPK suppresses HOG-LDL–induced ER
stress by inhibiting NAD(P)H oxidase–derived ROS and
SERCA oxidation. Therefore, AMPK may be a physiologi-
cal regulator that maintains ER homeostasis and endothe-
lial function. The proposed mechanism is outlined in
supplementary Fig. 4.
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